Drug Profile
Cardiovascular disorders therapeutic - Actelion
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Unknown
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals